Transition Therapeutics Inc.

101 College Street, Suite 220
M5G 1L7 Toronto
Canada

Contact

About Transition Therapeutics

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005/ AZD-103 for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine.

News about Transition Therapeutics

22-Jun-2009 | people

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

Transition Therapeutics Inc. announced that Ms. Laura Agensky has been appointed Vice-President of Clinical Operations. Since joining Transition in 2001, ...

Read news

22-Oct-2008 | research and development

Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)

Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 ( ...

Read news

20-Aug-2008 | business & finance

Transition Therapeutics Strengthens Drug Discovery Group

Transition Therapeutics Inc. announced a series of actions to strengthen the Company's drug discovery group. Transition has acquired certain assets and ...

Read news

31-Aug-2007 | research and development

Transition Therapeutics Announces Completion of Phase I Clinical Studies with Alzheimer's Disease Drug Candidate

Transition Therapeutics Inc. announced the completion of Phase I clinical studies with Alzheimer's disease drug candidate ELND-005/AZD-103. Transition and ...

Read news

05-Jun-2007 | business & finance

Transition Therapeutics Acquires All Remaining Shares of NeuroMedix Inc.

Transition Therapeutics Inc. announced that Transition has acquired all of the remaining outstanding common shares of NeuroMedix Inc. pursuant to the ...

Read news

14-May-2007 | business & finance

Transition Therapeutics Completes Tender Offer for CNS-Focused NeuroMedix Inc.

Transition Therapeutics Inc. and NeuroMedix Inc. announced the successful completion of Transition's tender offer for the outstanding shares of NeuroMedix ...

Read news

10-Apr-2007 | research and development

FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005

Transition Therapeutics Inc. announced that the United States Food and Drug Administration has granted Fast Track designation to investigational drug ...

Read news

23-Mar-2007 | business & finance